A large study assessed the risk of cancer in a RA cohort treated with anti-TNF-α and showed a relative risk (RR) of 1.00 (95% CI: 0.86–1.15) compared to the biotherapy naïve RA cohort. Here, TNF is linked to rheumatoid arthritis.